Bottom line
PJP vs GGHCX: the short answer
PJP (Invesco Pharmaceuticals ETF) and GGHCX (INVESCO Health Care Fund) are quite different portfolios: only about 36% of their top holdings (by weight) are shared.
But GGHCX is far broader, holding 82 positions to 33 for PJP, so beyond the top names it adds exposure PJP doesn't have.
PJP is cheaper at 0.58% vs 1.07% — a difference of $49 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +2.6% for GGHCX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
PJP vs GGHCX side by side
| PJP | GGHCX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Invesco | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 1.07% |
| Annual cost per $10k | $58 | $107 |
| 10-yr cost on $10k (prospectus) | $726 | $1,784 |
| Max front load | None | 5.5% |
| 12b-1 fee | — | 0.25% |
| 1-yr return | +27.9% | +9.2% |
| 5-yr return (annualized) | +9.0% | +2.6% |
| 10-yr return (annualized) | +5.1% | +5.8% |
| Best quarter | +18.1% | +19.6% |
| Worst quarter | −14.8% | −16.5% |
| Net assets (fund) | $472.1M | $1.2B |
| Number of holdings | 33 | 82 |
| Portfolio turnover | 36% | 59% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | GGHCX | Difference |
|---|---|---|---|
| 2025 | +27.9% | +15.5% | +12.4% |
| 2024 | +9.7% | +4.0% | +5.7% |
| 2023 | −2.2% | +3.1% | −5.3% |
| 2022 | −2.0% | −13.5% | +11.5% |
| 2021 | +14.5% | +12.2% | +2.3% |
| 2020 | +11.2% | +14.5% | −3.3% |
| 2019 | +4.7% | +32.0% | −27.3% |
| 2018 | −1.7% | +0.5% | −2.2% |
| 2017 | +15.3% | +15.5% | −0.1% |
| 2016 | −19.3% | −11.7% | −7.5% |
Source: Fund prospectus bar charts
Holdings overlap
8 of PJP's top 25 holdings also appear in GGHCX's top 25.
| Holding | PJP | GGHCX |
|---|---|---|
| Invesco Private Prime Fund | 7.93% | 4.67% |
| AbbVie Inc. | 5.48% | 4.03% |
| Johnson & Johnson | 5.18% | 6.76% |
| Merck & Co., Inc. | 5.06% | 4.59% |
| Eli Lilly and Co. | 5.02% | 10.59% |
| Gilead Sciences, Inc. | 4.53% | 3.63% |
| Invesco Private Government Fund | 3.73% | 1.80% |
| Ligand Pharmaceuticals Inc. | 3.20% | 1.18% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
FAQ
What is the difference between PJP and GGHCX?
Which is cheaper, PJP or GGHCX?
Should I own both PJP and GGHCX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.